{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:37:28Z","timestamp":1788871048013,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":868,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Actelion"},{"name":"Gilead"},{"name":"Lilly\/Icos"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007150","name":"United Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007150","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Actelion"},{"name":"Bayer"},{"name":"Gilead"},{"name":"LungRx"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007150","name":"United Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007150","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007150","name":"United Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007150","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Lung Rx"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.jacc.2010.11.020","type":"journal-article","created":{"date-parts":[[2011,2,23]],"date-time":"2011-02-23T05:03:02Z","timestamp":1298437382000},"page":"1053-1061","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Compelling Evidence of Long-Term Outcomes in Pulmonary Arterial Hypertension?"],"prefix":"10.1016","volume":"57","author":[{"given":"Mardi","family":"Gomberg-Maitland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Dufton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald J.","family":"Oudiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond L.","family":"Benza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl","key":"10.1016\/j.jacc.2010.11.020_bib1","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.jacc.2009.04.011","article-title":"Diagnosis and assessment of pulmonary arterial hypertension","volume":"54","author":"Badesch","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl","key":"10.1016\/j.jacc.2010.11.020_bib2","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jacc.2009.04.012","article-title":"Updated clinical classification of pulmonary hypertension","volume":"54","author":"Simonneau","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl","key":"10.1016\/j.jacc.2010.11.020_bib3","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jacc.2009.04.009","article-title":"Development and pathology of pulmonary hypertension","volume":"54","author":"Tuder","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl","key":"10.1016\/j.jacc.2010.11.020_bib4","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jacc.2009.04.018","article-title":"Cellular and molecular basis of pulmonary arterial hypertension","volume":"54","author":"Morrell","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl","key":"10.1016\/j.jacc.2010.11.020_bib5","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.jacc.2009.04.017","article-title":"Updated evidence-based treatment algorithm in pulmonary arterial hypertension","volume":"54","author":"Barst","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.11.020_bib7","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1164\/rccm.200204-333OC","article-title":"Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol","volume":"167","author":"Kuhn","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacc.2010.11.020_bib8","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1378\/chest.129.6.1636","article-title":"Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension","volume":"129","author":"Lang","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2010.11.020_bib9","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/eurheartj\/ehi728","article-title":"Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension","volume":"27","author":"Provencher","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2010.11.020_bib10","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival","volume":"40","author":"Sitbon","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.11.020_bib11","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Galie","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.11.020_bib12","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2","volume":"117","author":"Galie","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.11.020_bib13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1378\/chest.124.1.247","article-title":"Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study","volume":"124","author":"Sitbon","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2010.11.020_bib14","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1136\/ard.2005.048967","article-title":"Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions","volume":"65","author":"Denton","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jacc.2010.11.020_bib15","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Galie","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.11.020_bib16","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.jacc.2009.07.033","article-title":"Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension","volume":"54","author":"Oudiz","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.11.020_bib17","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: the impact of epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.11.020_bib18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cardfail.2009.09.008","article-title":"Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension","volume":"16","author":"Blalock","year":"2010","journal-title":"J Card Fail"},{"issue":"Suppl","key":"10.1016\/j.jacc.2010.11.020_bib19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2362.2006.01688.x","article-title":"Survival in patients with pulmonary arterial hypertension treated with first-line bosentan","volume":"36","author":"McLaughlin","year":"2006","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jacc.2010.11.020_bib20","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1136\/thx.2005.040618","article-title":"Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol","volume":"60","author":"Sitbon","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.jacc.2010.11.020_bib21","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1136\/ard.2007.079921","article-title":"Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases","volume":"67","author":"Denton","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jacc.2010.11.020_bib22","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1378\/chest.07-0767","article-title":"Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival","volume":"134","author":"Benza","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2010.11.020_bib23","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension","volume":"327","author":"Rich","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.11.020_bib24","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1161\/CIRCULATIONAHA.104.488486","article-title":"Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension","volume":"111","author":"Sitbon","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.11.020_bib25","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/0003-4819-121-6-199409150-00003","article-title":"Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin","volume":"121","author":"Barst","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2010.11.020_bib26","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1183\/09031936.06.00044406","article-title":"Long-term outcome in pulmonary arterial hypertension patients treated with treprostinil","volume":"28","author":"Barst","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacc.2010.11.020_bib27","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0735-1097(03)00463-7","article-title":"Beraprost therapy for pulmonary arterial hypertension","volume":"41","author":"Barst","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl","key":"10.1016\/j.jacc.2010.11.020_bib28","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/j.jacc.2009.04.007","article-title":"End points and clinical trial design in pulmonary arterial hypertension","volume":"54","author":"McLaughlin","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.11.020_bib29","doi-asserted-by":"crossref","first-page":"740","DOI":"10.7326\/0003-4819-130-9-199905040-00014","article-title":"Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series","volume":"130","author":"McLaughlin","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2010.11.020_bib30","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.11.020_bib31","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension","volume":"115","author":"D\u2019Alonzo","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2010.11.020_bib32","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1161\/01.CIR.80.2.353","article-title":"Two-dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension","volume":"80","author":"Eysmann","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.11.020_bib33","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1161\/01.CIR.89.4.1733","article-title":"Survival in primary pulmonary hypertension","volume":"89","author":"Sandoval","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.11.020_bib34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2169\/internalmedicine.38.12","article-title":"Prediction of life expectancy in patients with primary pulmonary hypertension","volume":"38","author":"Okada","year":"1999","journal-title":"Intern Med"},{"key":"10.1016\/j.jacc.2010.11.020_bib35","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1378\/chest.119.6.1801","article-title":"Primary pulmonary hypertension in Israel: a national survey","volume":"119","author":"Appelbaum","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2010.11.020_bib36","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1164\/ajrccm.161.2.9906015","article-title":"Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension","volume":"161","author":"Miyamoto","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacc.2010.11.020_bib37","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1164\/rccm.200307-957OC","article-title":"Sitaxsentan therapy for pulmonary arterial hypertension","volume":"169","author":"Barst","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacc.2010.11.020_bib38","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.11.020_bib39","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.11.020_bib40","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jacc.2006.01.057","article-title":"Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan","volume":"47","author":"Barst","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.11.020_bib41","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":"Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial","volume":"149","author":"Simonneau","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2010.11.020_bib42","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/eurheartj\/ehp022","article-title":"A meta-analysis of randomized controlled trials in pulmonary arterial hypertension","volume":"30","author":"Galie","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2010.11.020_bib43","doi-asserted-by":"crossref","first-page":"216","DOI":"10.7326\/0003-4819-107-2-216","article-title":"Primary pulmonary hypertension","volume":"107","author":"Rich","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2010.11.020_bib44","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1183\/09031936.00072709","article-title":"Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation","volume":"35","author":"Thenappan","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacc.2010.11.020_bib45","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","article-title":"Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)","volume":"122","author":"Benza","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.11.020_bib46","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/CIRCULATIONAHA.109.911818","article-title":"Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era","volume":"122","author":"Humbert","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.11.020_bib47","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1183\/09031936.00042107","article-title":"A USA-based registry for pulmonary arterial hypertension: 1982\u20132006","volume":"30","author":"Thenappan","year":"2007","journal-title":"Eur Respir J"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073510971004917X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073510971004917X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:42:09Z","timestamp":1760013729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073510971004917X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S073510971004917X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2010.11.020","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Compelling Evidence of Long-Term Outcomes in Pulmonary Arterial Hypertension?","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2010.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}